[Lipoprotein metabolism and beta receptor blockers].
Including own results a survey is given of the side effects of beta-receptor blockers on the plasma lipoprotein metabolism. The formation of a from the coronary-preventive point of view unfavourable lipoprotein risk profile under influence of individual beta-receptor blockers, among others propranolol, seems to be connected with an inhibition of a key enzyme in the lipoprotein metabolism, the lecithin-cholesterol-acyl transferase. Talinolol does not show these side effects. It is recommended to control the triglyceride level and the HDL cholesterol before the induction and after the beginning of a therapy with beta-receptor blockers and to use talinolol instead of propranolol in pre-existing dyslipoproteinaemia or in unfavourable changes during the treatment.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D001262:Atenolol / Q000009:adverse effects; D008076:Cholesterol, HDL / Q000097:blood; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000139:chemically induced*; D008074:Lipoproteins / Q000097:blood*; D008790:Metoprolol / Q000009:adverse effects; D011433:Propranolol / Q000009:adverse effects; D012306:Risk; D014280:Triglycerides / Q000097:blood
D000319:Adrenergic beta-Antagonists; D008076:Cholesterol, HDL; D008074:Lipoproteins; D014280:Triglycerides; D001262:Atenolol; D011433:Propranolol; D008790:Metoprolol
Lipoproteinstoffwechsel und beta-Rezeptorenblocker.